Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110).
暂无分享，去创建一个
V. Heinemann | T. Decker | C. Denzlinger | T. Kirchner | A. Jung | U. Graeven | S. Stintzing | L. Fischer von Weikersthal | M. Michl | J. Uhlig | D. Modest | A. Stahler | C. Giessen-Jung | S. Held | I. Ricard | M. Schenk | F. Kaiser | J. Freiberg-Richter | B. Peuser | K. Heinrich | C. Gießen-Jung